Acute_JJ
leukemia_NN
with_IN
promyelocytic_JJ
features_NNS
in_IN
PML\/RARalpha_NN
transgenic_JJ
mice_NNS
._.

Acute_JJ
promyelocytic_JJ
leukemia_NN
-LRB-_-LRB-
APL_NN
-RRB-_-RRB-
is_VBZ
associated_VBN
with_IN
reciprocal_JJ
chromosomal_JJ
translocations_NNS
involving_VBG
the_DT
retinoic_JJ
acid_NN
receptor_NN
alpha_NN
-LRB-_-LRB-
RARalpha_NN
-RRB-_-RRB-
locus_NN
on_IN
chromosome_NN
17_CD
._.

In_IN
the_DT
majority_NN
of_IN
cases_NNS
,_,
RARalpha_NN
translocates_VBZ
and_CC
fuses_VBZ
with_IN
the_DT
promyelocytic_JJ
leukemia_NN
-LRB-_-LRB-
PML_NN
-RRB-_-RRB-
gene_NN
located_JJ
on_IN
chromosome_NN
15_CD
._.

The_DT
resulting_VBG
fusion_NN
genes_NNS
encode_VBP
the_DT
two_CD
structurally_RB
unique_JJ
PML\/RARalpha_NN
and_CC
RARalpha\/PML_NN
fusion_NN
proteins_NNS
as_RB
well_RB
as_IN
aberrant_JJ
PML_NN
gene_NN
products_NNS
,_,
the_DT
respective_JJ
pathogenetic_JJ
roles_NNS
of_IN
which_WDT
have_VBP
not_RB
been_VBN
elucidated_VBN
._.

We_PRP
have_VBP
generated_VBN
transgenic_JJ
mice_NNS
in_IN
which_WDT
the_DT
PML\/RARalpha_NN
fusion_NN
protein_NN
is_VBZ
specifically_RB
expressed_VBN
in_IN
the_DT
myeloid-promyelocytic_JJ
lineage_NN
._.

During_IN
their_PRP$
first_JJ
year_NN
of_IN
life_NN
,_,
all_PDT
the_DT
PML\/RARalpha_NN
transgenic_JJ
mice_NNS
have_VBP
an_DT
abnormal_JJ
hematopoiesis_NN
that_WDT
can_MD
best_RBS
be_VB
described_VBN
as_IN
a_DT
myeloproliferative_JJ
disorder_NN
._.

Between_IN
12_CD
and_CC
14_CD
months_NNS
of_IN
age_NN
,_,
10_CD
%_NN
of_IN
them_PRP
develop_VBP
a_DT
form_NN
of_IN
acute_JJ
leukemia_NN
with_IN
a_DT
differentiation_NN
block_NN
at_IN
the_DT
promyelocytic_JJ
stage_NN
that_WDT
closely_RB
mimics_VBZ
human_JJ
APL_NN
even_RB
in_IN
its_PRP$
response_NN
to_TO
retinoic_JJ
acid_NN
._.

Our_PRP$
results_NNS
are_VBP
conclusive_JJ
in_IN
vivo_FW
evidence_NN
that_IN
PML\/RARalpha_NN
plays_VBZ
a_DT
crucial_JJ
role_NN
in_IN
the_DT
pathogenesis_NN
of_IN
APL_NN
._.

